Gabriela Steiner

ORCID: 0009-0004-0714-5525
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Immunotherapy and Immune Responses
  • vaccines and immunoinformatics approaches
  • SARS-CoV-2 and COVID-19 Research
  • Pharmacological Effects and Toxicity Studies
  • HIV/AIDS Research and Interventions
  • Monoclonal and Polyclonal Antibodies Research
  • HIV-related health complications and treatments
  • Lymphatic System and Diseases
  • Immune Cell Function and Interaction
  • Vascular Malformations and Hemangiomas
  • Opioid Use Disorder Treatment
  • Prenatal Substance Exposure Effects
  • Cancer Immunotherapy and Biomarkers
  • T-cell and B-cell Immunology
  • Migration, Health and Trauma
  • HIV, Drug Use, Sexual Risk
  • Alcoholism and Thiamine Deficiency
  • Melanoma and MAPK Pathways
  • Torture, Ethics, and Law
  • Lymphatic Disorders and Treatments

University of California, San Francisco
2022-2025

Parker Institute for Cancer Immunotherapy
2020-2023

Daniel K. Wells Marit M. van Buuren Kristen K. Dang Vanessa M. Hubbard-Lucey Kathleen C. F. Sheehan and 95 more Katie M. Campbell Andrew Lamb Jeffrey P. Ward John Sidney Ana-Belén Blázquez Andrew J. Rech Jesse M. Zaretsky Begonya Comin-Anduix Alphonsus H. C. Ng William Chour Thomas Yu Hira Rizvi Jia M. Chen Patrice Manning Gabriela Steiner Xengie Doan Taha Merghoub Justin Guinney Adam Kolom Cheryl Selinsky Antoni Ribas Matthew D. Hellmann Nir Hacohen Alessandro Sette James R. Heath Nina Bhardwaj Fred Ramsdell Robert D. Schreiber Ton N. Schumacher Pia Kvistborg Nadine A. Defranoux Aly A. Khan Amit A. Lugade Ana Mijalkovic Lazic Angela Frentzen Arbel D. Tadmor Ariella Sasson Arjun A. Rao Baikang Pei Barbara Schrörs Beata Berent-Maoz Beatriz M. Carreno Bin Song Bjoern Peters Bo Li Brandon W. Higgs Brian J. Stevenson Christian Iseli Christopher A. Miller Christopher Morehouse Cornelis J.M. Melief Cristina Puig-Saus Daphne M. van Beek David Balli David Gfeller David Haussler Dirk Jäger Eduardo Cortes Ekaterina Esaulova Elham Sherafat Francisco Arcila Gábor Bartha Geng Liu George Coukos Guilhem Richard Chang Han Han Si Inka Zörnig Ioannis Xénarios Ion Măndoiu Irsan Kooi James Conway Jan H. Kessler Jason Greenbaum Jason Perera Jason Harris Jasreet Hundal Jennifer Shelton Jianmin Wang Jiaqian Wang Joel Greshock Jonathon Blake Joseph D. Szustakowski Julia Kodysh Juliet Forman Lei Wei Leo J. Lee Lorenzo F. Fanchi Maarten Slagter Maren Lang Markus S. Mueller Martin Löwer Mathias Vormehr Maxim N. Artyomov Michael Kuziora

10.1016/j.cell.2020.09.015 article EN publisher-specific-oa Cell 2020-10-01

Immune checkpoint inhibitors (ICIs), including CTLA-4- and PD-1-blocking antibodies, can have profound effects on tumor immune cell infiltration that not been consistent in biopsy series reported to date. Here, we analyze seven molecular datasets of samples from patients with advanced melanoma (N = 514) treated ICI agents investigate clinical, genomic, transcriptomic features anti-PD-1 response cutaneous melanoma. We find prior anti-CTLA-4 therapy is associated differences individual gene,...

10.1016/j.ccell.2023.03.010 article EN cc-by Cancer Cell 2023-04-01

Summary SARS-CoV-2 T cell response assessment and vaccine development may benefit from an approach that considers the global landscape of human leukocyte antigen (HLA) proteins. We predicted binding affinity between 9-mer 15-mer peptides peptidome for 9,360 class I 8,445 II HLA alleles, respectively. identified 368,145 unique combinations peptide-HLA complexes (pMHCs) with a less than 500nM, observed significant overlap pMHCs. Using simulated populations derived worldwide frequency data, we...

10.1101/2020.03.30.016931 preprint EN cc-by-nc-nd bioRxiv (Cold Spring Harbor Laboratory) 2020-04-01

Abstract Background Fentanyl use leads to increased opioid tolerance in people with disorder, complicating management of withdrawal syndrome. While accepted as gold standard, methadone and buprenorphine may be insufficient treat acute withdrawal. Short-acting full agonist opioids (SAFAO) improve treatment the care setting. Aim Characterize SAFAO syndrome for inpatients. Setting Urban safety-net hospital. Participants Inpatients disorder. Program Description Addiction Consult Team offers...

10.1007/s11606-024-09321-5 article EN cc-by Journal of General Internal Medicine 2025-01-06

Abstract Introduction: Delineating antiviral T-cell responses to SARS-CoV-2 may shed light on the heterogeneity of clinical outcomes and inform vaccine or therapeutic approaches. Viral antigens can be predicted using computational tools that calculate binding affinity between viral peptides antigen presentation machinery. However, in order account for role host genetics diversity responses, this analysis must performed with consideration global human leukocyte (HLA) proteins responsible...

10.1158/1557-3265.covid-19-s03-01 article EN Clinical Cancer Research 2020-09-15

Introduction This research, through the analysis of case-law Inter-American Court Human Rights (IACtHR), seeks to shed light on nexus between families missing' claims, their agency and State compliance with reparations. The IACtHR has a unique follow-up system in area reparations, where victims can directly address judges during hearings. paper suggests that victims' participation - before after judgment- pervades legal rigidity international jurisdictions contributes better understanding...

10.7146/torture.v32i3.130227 article EN cc-by-nc-nd Torture Journal 2022-09-14

OBJECTIVES/GOALS: Contingency management (CM), wherein patients earn prizes for behavior change, is the gold-standard reducing stimulant misuseand has been shown to improve medication adherence.We aim describe feasibility, acceptability, and effectiveness of CM reduce use optimize ART adherence in Women’s HIV primary care. METHODS/STUDY POPULATION: Using ADAPT-ITT model adapting evidence-based interventions, we implemented CoMBostudy at Ward 86 Clinic San Francisco General Hospital....

10.1017/cts.2024.213 article EN cc-by-nc-nd Journal of Clinical and Translational Science 2024-04-01

<sec> <title>BACKGROUND</title> Amongst people living with HIV, stimulant use disorder (StUD) has been linked medication non-adherence and mortality. Contingency management (CM) is a strategy incentivizing measurable behavior change that recommended as first-line treatment for StUD can support antiretroviral therapy (ART) adherence. However, CM not widely implemented, in part due to feasibility concerns. While reductions substance short of abstinence improve health outcomes, programs...

10.2196/preprints.67292 preprint EN 2024-10-08
Coming Soon ...